US Pharma MarketingSpyre drops rheumatoid arthritis hopes for anti-TL1A drug after modest Phase 2 data
Spyre deprioritizes anti-TL1A drug SPY072 in RA after Phase 2 misses its bar; shares dip 12% as SKYLINE UC data nears in September. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The…
Spyre Therapeutics said Tuesday it is deprioritizing its antibody candidate for rheumatoid arthritis (RA) after the drug missed the biotech’s bar for success in a mid-stage trial.
The results also put a dampener on the ...
Source: Endpoints News